- Home
- TPCS vs BCAB Comparison
TPCS vs BCAB Comparison
Compare TPCS & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPCS
- BCAB
- Stock Information
- Founded
- TPCS 1956
- BCAB 2007
- Country
- TPCS United States
- BCAB United States
- Employees
- TPCS N/A
- BCAB N/A
- Industry
- TPCS Metal Fabrications
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- TPCS Industrials
- BCAB Health Care
- Exchange
- TPCS Nasdaq
- BCAB Nasdaq
- Market Cap
- TPCS 31.5M
- BCAB 28.6M
- IPO Year
- TPCS N/A
- BCAB 2020
- Fundamental
- Price
- TPCS $3.20
- BCAB $0.46
- Analyst Decision
- TPCS
- BCAB Buy
- Analyst Count
- TPCS 0
- BCAB 2
- Target Price
- TPCS N/A
- BCAB $5.00
- AVG Volume (30 Days)
- TPCS 25.4K
- BCAB 990.6K
- Earning Date
- TPCS 01-21-2025
- BCAB 03-25-2025
- Dividend Yield
- TPCS N/A
- BCAB N/A
- EPS Growth
- TPCS N/A
- BCAB N/A
- EPS
- TPCS N/A
- BCAB N/A
- Revenue
- TPCS $33,182,059.00
- BCAB $11,000,000.00
- Revenue This Year
- TPCS N/A
- BCAB N/A
- Revenue Next Year
- TPCS N/A
- BCAB N/A
- P/E Ratio
- TPCS N/A
- BCAB N/A
- Revenue Growth
- TPCS 6.44
- BCAB N/A
- 52 Week Low
- TPCS $2.85
- BCAB $0.43
- 52 Week High
- TPCS $5.95
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- TPCS 46.13
- BCAB 23.28
- Support Level
- TPCS $3.06
- BCAB $0.46
- Resistance Level
- TPCS $3.25
- BCAB $0.49
- Average True Range (ATR)
- TPCS 0.14
- BCAB 0.04
- MACD
- TPCS 0.00
- BCAB 0.03
- Stochastic Oscillator
- TPCS 50.00
- BCAB 27.98
About TPCS TechPrecision Corporation Common stock
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.